{
    "doi": "https://doi.org/10.1182/blood.V130.Suppl_1.897.897",
    "start_url": "https://ashpublications.org/blood/search-results?sort=Date+-+Oldest+First&f_ArticleTypeDisplayName=Meeting+Report&fl_SiteID=1000001&page=3744",
    "start_url_page_num": 3744,
    "is_scraped": "1",
    "article_title": "Final Evaluation of Randomized CML-Study IV: 10-Year Survival and Evolution of Terminal Phase ",
    "article_date": "December 7, 2017",
    "session_type": "632: Chronic Myeloid Leukemia: Therapy: Results of Clinical Trials",
    "topics": [
        "arm",
        "blast phase",
        "chromosome abnormality",
        "comorbidity",
        "cytarabine",
        "disclosure",
        "drug administration routes",
        "employment",
        "imatinib mesylate",
        "leukemia"
    ],
    "author_names": [
        "R\u00fcdiger Hehlmann, MD",
        "Michael Lauseker, PhD",
        "Susanne Saussele, MD",
        "Markus Pfirrmann",
        "Stefan W. Krause, MD",
        "Hans-Jochem Kolb, MD",
        "Andreas Neubauer, MD",
        "Dieter K. Hossfeld",
        "Christoph Nerl, MD",
        "Alois Gratwohl, MD",
        "Gabriela M. Baerlocher",
        "Dominik Heim, MD",
        "Tim Henrik Bruemmendorf",
        "Alice Fabarius, PhD",
        "Claudia Haferlach, MD",
        "Brigitte Schlegelberger, MD PhD",
        "Martin C. M\u00fcller, MD",
        "Sabine Jeromin, PhD",
        "Ulrike Proetel, PhD",
        "Katharina Kohlbrenner, PhD",
        "Astghik Voskanyan, PhD",
        "S\u00e9bastien Rinaldetti",
        "Wolfgang Seifarth, PhD",
        "Birgit Spiess",
        "Leopold Balleisen, MD",
        "Maria E Goebeler, MD",
        "Mathias H\u00e4nel, MD",
        "Anthony D. Ho, MD",
        "J Dengler",
        "C Falge",
        "Lothar Kanz, MD",
        "Claus-Henning K\u00f6hne, MD, PhD",
        "Andreas Burchert, MD",
        "Michael Kneba, MD PhD",
        "Frank Stegelmann, MD",
        "C K\u00f6hne",
        "Hans-Walter Lindemann",
        "C Waller",
        "Michael Pfreundschuh, MD",
        "Karsten Spiekermann",
        "Wolfgang E Berdel, MD",
        "L M\u00fcller",
        "Matthias Edinger, MD",
        "Jiri Mayer, Prof, MD SCs",
        "Dietrich W Beelen, MD PhD",
        "Martin Bentz, MD",
        "Hartmut Link, MDPhD",
        "Bernd Hertenstein, MD",
        "R Fuchs",
        "Martin Wernli, MD",
        "F Schlegel",
        "Rudolph Schlag",
        "M de Wit",
        "Lorenz Tr\u00fcmper, MD",
        "H Hebarth",
        "M Hahn",
        "J\u00f6rg Thomalla, MD",
        "Christof Scheid, MD",
        "Philippe Schafhausen, MD",
        "Walter Verbeek, MD",
        "Michael J. Eckart, MD",
        "Winfried Gassmann, MD PhD",
        "Antonio Pezzutto, MD",
        "Michael Schenk",
        "Peter Brossart, MD",
        "Thomas Geer, MD",
        "Stephan Bildat",
        "E Sch\u00e4fer",
        "Andreas Hochhaus, MD",
        "Joerg Hasford"
    ],
    "author_affiliations": [
        [
            "III. Medizinische Klinik, Medizinische Fakult\u00e4t Mannheim der Uni Heidelberg, Mannheim, Germany "
        ],
        [
            "Institut f\u00fcr Medizinische Informationsverarbeitung, Biometrie und Epidemiologie, Ludwig-Maximilians-Universit\u00e4t M\u00fcnchen, M\u00fcnchen, Germany "
        ],
        [
            "III. Medizinische Klinik, Universit\u00e4tsmedizin Mannheim, Universit\u00e4t Heidelberg, Mannheim, Germany "
        ],
        [
            "Institut f\u00fcr medizinische Informationsverarbeitung, Biometrie und Epidemiologie, Ludwig-Maximilians-Universit\u00e4t, M\u00fcnchen, Germany "
        ],
        [
            "Department of Internal Medicine 5, Haematology/Oncology, University of Erlangen, Erlangen, Germany "
        ],
        [
            "Department of Internal Medicine III, University of Munich-Grosshadern, Munich, Germany "
        ],
        [
            "Department of Hematology and Oncology, University Hospital Giessen and Marburg, Marburg, Germany "
        ],
        [
            "II. Medizinische Klinik, Universit\u00e4tsklinikum Hamburg-Eppendorf (UKE), Hamburg, Germany "
        ],
        [
            "Klinik f\u00fcr H\u00e4matologie, Onkologie, Immunologie, Palliativmedizin, Infektiologie und Tropenmedizin, Klinikum Schwabing, M\u00fcnchen, Germany "
        ],
        [
            "Hematology, University Hospital of Basel, Basel, Switzerland "
        ],
        [
            "Universit\u00e4tsklinik f\u00fcr H\u00e4matologie und h\u00e4matologisches Zentrallabor, Inselspital, Bern, Switzerland "
        ],
        [
            "Klinik f\u00fcr H\u00e4matologie, Universit\u00e4tsspital, Basel, Switzerland "
        ],
        [
            "Direktor der Klinik f\u00fcr Onkologie, H\u00e4matologie und Stammzelltransplantation Euregionales Comprehensive Cancer Center Aachen (ECCA), Aachen, Germany "
        ],
        [
            "III. Medizinische Klinik, Medizinische Fakult\u00e4t Mannheim der Uni Heidelberg, Mannheim, Germany "
        ],
        [
            "MLL Munich Leukemia Laboratory GmbH, Munich, Germany "
        ],
        [
            "Institute of Cell and Molecular Pathology, Hannover Medical School, Hannover, Germany "
        ],
        [
            "III. Medizinische Klinik, Medizinische Fakult\u00e4t Mannheim der Uni Heidelberg, Mannheim, Germany "
        ],
        [
            "MLL Munich Leukemia Laboratory, Munich, Germany "
        ],
        [
            "III. Medizinische Klinik, Universit\u00e4t Heidelberg, Medizinische Fakult\u00e4t, Mannheim, Germany "
        ],
        [
            "III. Med. Klinik, Medizinische Fakult\u00e4t Mannheim der Universit\u00e4t Heidelberg, Mannheim, Germany "
        ],
        [
            "Medizinische Fakult\u00e4t Mannheim der Universit\u00e4t Heidelberg, Mannheim, Germany "
        ],
        [
            "III. Medizinische Klinik, Medizinische Fakult\u00e4t Mannheim der Uni Heidelberg, Mannheim, Germany "
        ],
        [
            "Department of Hematology and Oncology, Medical Faculty Mannheim of the University of Heidelberg, Mannheim, Germany "
        ],
        [
            "University Hospital Mannheim, Heidelberg University, Department of Hematology and Oncology, Mannheim, Germany "
        ],
        [
            "Evangelisches Krankenhaus, Hamm, DEU "
        ],
        [
            "Leitung CCC Trial Office, W\u00fcrzburg, Germany "
        ],
        [
            "Klinikum Chemnitz, Chemnitz, Germany "
        ],
        [
            "Medizinische Klinik V, Universit\u00e4tsklinikum Heidelberg, Heidelberg, Germany "
        ],
        [
            "Schwerpunktpraxis Heildbronn, Heilbronn, Germany "
        ],
        [
            "Klinikum N\u00fcrnberg Nord, N\u00fcrnberg, Germany "
        ],
        [
            "Department of Oncology, Hematology, Immunology, Rheumatology and Pulmonology, University Hospital Tuebingen, Tuebingen, Germany, Tuebingen, Germany "
        ],
        [
            "Klinik f\u00fcr Onkologie und H\u00e4matologie, Klinikum Oldenburg, Oldenburg, Germany "
        ],
        [
            "Hem./Onc./Immunology, University of Marburg, Marburg, Germany "
        ],
        [
            "Department of Internal Medicine II, University Hospital of Schleswig-Holstein, Campus Kiel, Kiel, Germany "
        ],
        [
            "Department of Internal Medicine III, University Hospital of Ulm, Germany, Ulm, Germany "
        ],
        [
            "Klinik f\u00fcr Innere Medizin I, Universit\u00e4t des Saarlandes, Homburg, Homburg, Germany "
        ],
        [
            "Klinik f\u00fcr H\u00e4matologie / Onkologie, Kath. Krankenhaus Hagen gem. GmbH - St.-Marien-Hospital, Hagen, Germany "
        ],
        [
            "Universit\u00e4tsklinikum Freiburg, Freiburg, Germany "
        ],
        [
            "Jos\u00e9 Carreras Center for Immuno- and Gene Therapy and Internal Medicine I, Universit\u00e4t des Saarlandes, Homburg, Germany ",
            "Innere Medizin I, Universit\u00e4t des Saarlandes, Homburg, Germany "
        ],
        [
            "Department of Internal Medicine III, University Hospital Grosshadern, Ludwig-Maximilians-Universit\u00e4t, Munich, Germany "
        ],
        [
            "Department of Medicine A - Hematology and Oncology, University Hospital of Muenster, Muenster, Germany "
        ],
        [
            "MLL M\u00fcnchen, M\u00fcnchen, Germany "
        ],
        [
            "Abteilung H\u00e4matologie und Internistische Onkologie, Universit\u00e4tsklinikum, Regensburg, Germany "
        ],
        [
            "Department of Internal Medicine, Hematology and Oncology, Masaryk University and University Hospital Brno, Brno, Czech Republic "
        ],
        [
            "Department of Bone Marrow Transplantation, West German Cancer Center, University of Duisburg-Essen, Essen, Germany "
        ],
        [
            "Department of Internal Medicine III, Municipal Hospital of Karlsruhe, Karlsruhe, Germany "
        ],
        [
            "Medizinische Klinik I Westpfalz-Klinikum, Kaiserslautern, Germany "
        ],
        [
            "I. Medizinische Klinik, Klinikum Bremen-Mitte, Bremen, Germany "
        ],
        [
            "Medizinische Klinik IV, Uniklinik RWTH Aachen, Aachen, Germany "
        ],
        [
            "Onkologie/H\u00e4matologie, Kantonsspital, Aarau, Switzerland "
        ],
        [
            "Schwerpunkt H\u00e4matologie / Internistische Onkologie, Stauferklinikum Schw\u00e4bisch Gm\u00fcnd, Mutlangen, Mutlangen, Germany "
        ],
        [
            "Ambulantes Onkologie-Zentrum, Ansbach, Wurzburg, DEU "
        ],
        [
            "Klinik I f\u00fcr Innere Medizin, Universit\u00e4tsklinikum K\u00f6ln, K\u00f6ln, Germany "
        ],
        [
            "Department of Hematology and Oncology, Universit\u00e4tsmedizin G\u00f6ttingen, Georg-August-Universit\u00e4t, G\u00f6ttingen, Germany "
        ],
        [
            "Internistische Schwerpunktpraxis Erlangen, Erlangen, Germany "
        ],
        [
            "Medizinische Klinik mit Schwerpunkt H\u00e4matologie und Onkologie, Campus Benjamin Franklin, Charit\u00e9, Berlin, Berlin, Germany "
        ],
        [
            "Praxisklinik f\u00fcr H\u00e4matologie und Onkologie, Koblenz, Germany "
        ],
        [
            "University of Cologne, Cologne, Germany "
        ],
        [
            "Department of Hematology and Oncology with Sections BMT and Pneumology, Hubertus Wald Tumorzentrum, University Hospital Hamburg-Eppendorf, Hamburg, Germany "
        ],
        [
            "Center of Outpatient Hematology/Oncology, Bonn, Germany "
        ],
        [
            "Onkologische Schwerpunktpraxis Erlangen, Erlangen, Germany "
        ],
        [
            "St. Marien-Krankenhaus gGmbH, Siegen, Germany "
        ],
        [
            "Charite Research Organization, Berlin, Germany "
        ],
        [
            "Krankenhaus Barmherzige Br\u00fcder, Regensburg, Germany "
        ],
        [
            "Department of Internal Medicine III, Oncology, Hematology and Rheumatology, University Hospital Bonn, Bonn, Germany "
        ],
        [
            "Innere Medizin H\u00e4matologie und Onkologie, Schwabisch Hall, Germany "
        ],
        [
            "Klinikum Herford, Herford, Germany "
        ],
        [
            "Onkologische Schwerpunktpraxis Bielefeld, Bielefeld, Germany "
        ],
        [
            "Jena University Hospital, Jena, Germany"
        ],
        [
            "Institut f\u00fcr medizinische Informationsverarbeitung, Biometrie und Epidemiologie, Ludwig-Maximilians-Universit\u00e4t, M\u00fcnchen, Germany "
        ]
    ],
    "first_author_latitude": "49.4924375",
    "first_author_longitude": "8.486733399999999",
    "abstract_text": "Background Chronic myeloid leukemia (CML)-study IV was designed to explore whether treatment with imatinib (IM) at 400mg/day (n=400) could be optimized by doubling the dose (n=420), adding IFN (n=430) or cytarabine (n=158) or using IM after IFN-failure (n=128). Methods From July 2002 to March 2012, 1551 newly diagnosed patients in chronic phase were randomized into a 5-arm study. The study was powered to detect a survival difference of 5% at 5 years. The impact of patients' and disease factors on survival was prospectively analyzed. At the time of evaluation, at least 62% of patients still received imatinib, 26.2% were switched to 2 nd generation tyrosine kinase inhibitors. Results After a median observation time of 9.5 years, 10-year overall survival was 82%, 10-year progression-free survival 80% and 10-year relative survival 92%. In spite of a faster response with IM800mg, the survival difference between IM400mg and IM800mg was only 3% at 5 years. In a multivariate analysis, the influence on survival of risk-group, major-route chromosomal aberrations, comorbidities, smoking and treatment center (academic vs. other) was significant in contrast to any form of initial treatment optimization. Patients that reached the response milestones 3, 6 and 12 months, had a significant survival advantage of about 6% after 10 years regardless of therapy. The progression probability to blast crisis was 5.8%. Blast crisis was proceeded by high-risk additional chromosomal aberrations. Conclusions For responders, monotherapy with IM400mg provides a close to normal life expectancy independent of the time to response. Survival is more determined by patients' and disease factors than by initial treatment selection. Although improvements are also needed for refractory disease and blast crisis, more life-time can currently be gained by carefully addressing non-CML determinants of survival. Disclosures Hehlmann: Novartis: Research Funding; BMS: Consultancy. Saussele: Pfizer: Honoraria; Incyte: Honoraria; Novartis: Honoraria, Research Funding; BMS: Honoraria, Research Funding. Pfirrmann: BMS: Honoraria; Novartis: Honoraria. Krause: Novartis: Honoraria. Baerlocher: Novartis: Honoraria; BMS: Honoraria; Pfizer: Honoraria. Bruemmendorf: Novartis: Research Funding. M\u00fcller: Novartis: Honoraria, Research Funding; BMS: Honoraria, Research Funding; Ariad: Honoraria, Research Funding; Pfizer: Honoraria, Research Funding. Jeromin: MLL Munich Leukemia Laboratory: Employment. H\u00e4nel: Roche: Honoraria; Novartis: Honoraria. Burchert: BMS: Honoraria. Waller: Mylan: Consultancy, Honoraria. Mayer: Eisai: Research Funding; Novartis: Research Funding. Link: Novartis: Honoraria. Scheid: Novartis: Honoraria. Schafhausen: Novartis: Honoraria; BMS: Honoraria; Pfizer: Honoraria; Ariad: Honoraria. Hochhaus: Incyte: Research Funding; MSD: Research Funding; Pfizer: Research Funding; Novartis: Research Funding; BMS: Research Funding; ARIAD: Research Funding."
}